Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Outcomes of Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A Case Series

NCT07224880 is registered in ClinicalTrials.gov with Cytrellis Biosystems, Inc. as lead sponsor.

NCT NCT07224880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07224880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Outcomes of Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A Case Series
Lead sponsor
Cytrellis Biosystems, Inc.
Phase
Observational
Overall status
Completed
Start date
October 14, 2025
Completion date
August 21, 2026
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gene expression, glp1 agonist, skin laxity